Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Magellan Health : Rx Management Oncology Biosimilar Solution Delivers $40M+ in Annualized Savings for Early Adopter Health Plans

06/09/2021 | 06:32am EDT

  • Health plans who adopted the program have experienced over 20% savings by switching to lower-cost biosimilars
  • The proprietary prior authorization process integrates seamlessly, limiting disruption within the provider network while maintaining high-quality care for members
  • When deployed with appropriate benefit designs, members may enjoy lower out of pocket costs with the biosimilars given the cost differential between oncology biosimilars and their reference brands

Magellan Rx Management, a division of Magellan Health, Inc. (NASDAQ: MGLN), today announced annualized savings of over $40 million for five health plan customers who were early adopters of its oncology biosimilar medical benefit drug management solution. This comprehensive approach encourages the use of oncology therapeutic biosimilars over more expensive reference products, when clinically appropriate. Savings figures are expected to grow even further as more customers have adopted the program since its inception and the market shift to biosimilars accelerates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005124/en/

Magellan Rx Management (Grapic: Business Wire)

Magellan Rx Management (Grapic: Business Wire)

“Magellan Rx continues to be a market leader and disrupter in delivering leading-edge solutions for the evolving healthcare landscape, and our health plan partners are recognizing real savings through these programs while maintaining a high quality level of care for their members,” said Steve Cutts, PharmD, senior vice president and general manager, specialty, Magellan Rx Management. “We have been tracking the emergence of biosimilars and started to deliver biosimilar-first solutions as early as 2016. It’s our commitment to staying ahead of the trend that has made us a trusted partner in medical benefit management for nearly two decades.”

Health plan customers implemented the program, which focuses on promotion of biosimilars for three oncology products, on or before January 1, 2020. Most of the current savings were achieved with the first two products that had biosimilar availability (see graphic), and preliminary results with the third product are promising. According to Magellan Rx’s internal data, these biosimilars can cost payers up to 40% less than their respective reference brands.

“We knew we wanted to collaborate with a medical pharmacy expert,” said Carly Rodriguez, pharmacy director at Moda Health, a health plan that implemented the program with success. “We were looking for a partner that would do more than save our plan on rising specialty costs, but that would continue to support our members with Moda’s signature quality of care. In partnering with Magellan Rx, we know we have the right experts on our side and we anticipate expanding the program to additional biosimilar agents, as clinically appropriate.”

These positive results, after just one year, reflect the growing need for management programs that deliver lower cancer treatment costs for payers and patients while maintaining high standards of care. Magellan Rx develops cost-effective and leading-edge strategies for medical benefit drug management across several categories, offering flexible solutions that can also operate outside of the traditional payer-PBM relationship. Health plans can leverage the extensive clinical expertise and experience at Magellan Rx by delegating specialty and medical drug management services while retaining a separate PBM. Read more about Magellan Rx’s total specialty drug management solutions. To learn more about Magellan Rx Management’s history of biosimilar management, visit, Magellan Insights.

About Magellan Rx Management: Magellan Rx Management, a division of Magellan Health, Inc., is a next-generation pharmacy organization that is delivering meaningful solutions to the people we serve. As pioneers in specialty drug management, industry leaders in Medicaid pharmacy programs and disruptors in pharmacy benefit management, we partner with our customers and members to deliver a best-in-class healthcare experience.

About Magellan Health: Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.


ę Business Wire 2021
All news about MAGELLAN HEALTH, INC.
09/15MAGELLAN HEALTH : Rx Management's AIDS Drug Assistance Program Center of Excellence Expand..
09/01MAGELLAN HEALTH : Provides Free Consultation Services and Referrals to Local Community Res..
08/30MAGELLAN HEALTH : Growth and Innovation Division at Magellan Health Announces New Appointm..
08/30Magellan Health, Inc. Announces Executive Appointments
08/26MAGELLAN HEALTH : Unit Launches Video Game Platform for Children's Mental Health
08/26MAGELLAN HEALTH : Healthcare Launches Clinically Proven Video Game Solution to Support Emo..
08/24MAGELLAN HEALTH : Healthcare Offers Ecosystem of Services for Suicide Prevention
08/18MAGELLAN HEALTH : Healthcare Launches eMbolden Resilience Program
08/05MAGELLAN HEALTH : Management's Discussion and Analysis of Financial Condition and Results ..
08/05MAGELLAN HEALTH : Q2 Earnings Snapshot
More news
Analyst Recommendations on MAGELLAN HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 4 808 M - -
Net income 2021 35,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 76,6x
Yield 2021 -
Capitalization 2 485 M 2 485 M -
Capi. / Sales 2021 0,52x
Capi. / Sales 2022 0,48x
Nbr of Employees 9 000
Free-Float 46,2%
Duration : Period :
Magellan Health, Inc. Technical Analysis Chart | MGLN | US5590792074 | MarketScreener
Technical analysis trends MAGELLAN HEALTH, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 1
Last Close Price 94,61 $
Average target price 95,00 $
Spread / Average Target 0,41%
EPS Revisions
Managers and Directors
Kenneth J. Fasola Chief Executive Officer & Director
James E. Murray President & Chief Operating Officer
David Patrick Bourdon Chief Financial Officer
Steve J. Shulman Chairman
Caroline Carney Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTHEM, INC.18.44%92 974
HUMANA INC.-2.15%51 262